CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $4.23B, above the global median of $1.18B
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
4.23BUSDvs all stocks (USD)
Trailing P/E
12.96xRevenue (TTM)
1.33BUSDvs all stocks (USD)
Profit Margin
26.75%Beta
1.14xvs all stocks
52-Week Change
47.99%vs all stocks
Market Capitalization
4.23BUSDvs all stocks (USD)
Enterprise Value
4.56BUSDvs all stocks (USD)
Trailing P/E
12.96xForward P/E
7.40xPEG Ratio
0.0223xPrice to Sales (TTM)
3.21xEnterprise to Revenue
3.42xEnterprise to EBITDA
7.91xGross Margin
85.42%Profit Margin
26.75%Operating Margin
46.94%Return on Assets (TTM)
26.40%Revenue (TTM)
1.33BUSDvs all stocks (USD)
Revenue per Share (TTM)
10.78USDUpdated Aug 27, 2026Quarterly Revenue Growth
13.60%Gross Profit (TTM)
1.14BUSDvs all stocks (USD)
EBITDA (TTM)
457.00MUSDvs all stocks (USD)
Net Income (TTM)
356.00MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
577.80%Operating Cash Flow (TTM)
-40.00MUSDvs all stocks (USD)
Payout Ratio
0.00%Revenue
1.24BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
246.00MUSDFY2025 · Dec 31, 2025Gross Profit
993.00MUSDFY2025 · Dec 31, 2025Operating Income
265.00MUSDvs all stocks (USD)
Pre-tax Income
239.00MUSDFY2025 · Dec 31, 2025Income Tax Expense
29.00MUSDFY2025 · Dec 31, 2025Net Income
210.00MUSDFY2025 · Dec 31, 2025EBIT
284.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
307.00MUSDFY2025 · Dec 31, 2025Research & Development
97.00MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
634.00MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-3.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
22.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
45.00MUSDFY2025 · Dec 31, 2025EPS (Basic)
1.68USDFY2025 · Dec 31, 2025EPS (Diluted)
1.64USDFY2025 · Dec 31, 2025Basic Shares Outstanding
125.00MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
125.00MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
210.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
321.00MUSDFY2025 · Dec 31, 2025Free Cash Flow
255.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
195.00MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
210.00MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
20.00MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-46.00MUSDFY2025 · Dec 31, 2025Stock-based Compensation
26.00MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
3.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
108.00MUSDFY2025 · Dec 31, 2025Capital Expenditures
-66.00MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.00MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-20.00MUSDFY2025 · Dec 31, 2025Sale of Investments
20.00MUSDFY2025 · Dec 31, 2025Other Investing Activity
1.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-65.00MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-17.00MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-11.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-4.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-30.00MUSDFY2025 · Dec 31, 2025Shares Outstanding
118.00MSharesUpdated Aug 27, 2026Float Shares
116.04MSharesUpdated Aug 27, 2026Shares Short
10.88MSharesUpdated Aug 27, 2026Short Ratio
7.11daysvs all stocks
Short % of Shares Outstanding
10.95%vs all stocks
% Held by Insiders
2.02%vs all stocks
% Held by Institutions
99.04%vs all stocks
Total Cash (MRQ)
222.00MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.88USDUpdated Aug 27, 2026Total Debt (MRQ)
509.00MUSDvs all stocks (USD)
Current Ratio (MRQ)
0.8350xBook Value per Share (MRQ)
-1.76USDUpdated Aug 27, 2026Total Assets
1.20BUSDvs all stocks (USD)
Total Current Assets
652.00MUSDFY2025 · Dec 31, 2025Total Liabilities
1.30BUSDFY2025 · Dec 31, 2025Total Non-current Assets
550.00MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
386.00MUSDFY2025 · Dec 31, 2025Total Current Liabilities
914.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
195.00MUSDFY2025 · Dec 31, 2025Other Short-term Investments
0.00USDFY2025 · Dec 31, 2025Accounts Receivable
253.00MUSDFY2025 · Dec 31, 2025Inventory
155.00MUSDFY2025 · Dec 31, 2025Accounts Payable
48.00MUSDFY2025 · Dec 31, 2025Short-term Debt
39.00MUSDFY2025 · Dec 31, 2025Other Current Liabilities
-1.00MUSDFY2025 · Dec 31, 2025Long-term Debt
312.00MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
22.00MUSDFY2025 · Dec 31, 2025Common Stock (Book)
62.00MUSDFY2025 · Dec 31, 2025Retained Earnings
-243.00MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-99.00MUSDvs all stocks (USD)
52-Week Low
22.22USDUpdated Aug 27, 202652-Week High
42.81USDUpdated Aug 27, 202652-Week Change
47.99%vs all stocks
Beta
1.14xvs all stocks
50-Day MA
39.52USDUpdated Aug 27, 2026200-Day MA
35.43USDUpdated Aug 27, 2026Avg 10-Day Volume
1.86MSharesUpdated Aug 27, 2026Avg 30-Day Volume
2.19MSharesUpdated Aug 27, 2026Diluted EPS (TTM)
2.79USDUpdated Aug 27, 2026Other Income / Expense
-3.00MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 356,000,000Operating Cash Flow (USD, TTM): -40,000,000
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $4.23B, above the global median of $1.18BNotable
Market cap (USD): 4,227,838,975Global Median: 1,179,398,897.704
Revenue is $1.33B, above the global median of $534.05MNotable
Revenue (USD): 1,331,000,064Global Median: 534,052,387.958
Companies that share the same coordination system — how they create, deliver, or capture value.
Veradermics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Relay Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Integer Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRule
Tango Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Chongqing Zhifei Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xuanzhu Biopharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Pharmaceutical Da Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Medical System Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Amylyx Pharmaceuticals, Inc. Common Stock
Tier 1ProductionApproval-Gated PipelineRule